Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2467${count})

  • ASAP CRN Competitive Renewal Opportunity, 2024
    Studying Basal Ganglia Networks in Parkinson's Disease

    Study Rationale: People with Parkinson's disease (PD) have long been known to display remarkable motor abilities under special circumstances, such as situations that involve strong emotions or stress...

  • ASAP CRN Competitive Renewal Opportunity, 2024
    Determining the Role of Proteins Associated with Parkinson’s Disease in T cell-Mediated Destruction of Dopamine Neurons
    ASAP logo

    Study Rationale: Before Parkinson's disease (PD) manifests its characteristic symptoms, the pathological process has been underway for years. Although the initial trigger remains uncertain, we have...

  • ASAP CRN Competitive Renewal Opportunity, 2024
    Circuit Mechanisms for Dopamine Neuron Vulnerability and Resilience in Parkinson’s Disease
    ASAP logo

    Study Rationale: Dopamine neurons are particularly vulnerable to death in Parkinson’s disease (PD), and their loss is one of the main causes of movement problems in people with PD. Dopamine neurons...

  • Parkinson’s Disease Therapeutics Pipeline Program, 2024
    A Novel Approach to Activating Glucosylceramidase in People with Parkinson’s Disease

    Study Rationale: Genetic mutations resulting in a depletion of glucosylceramidase activity is the most predisposing risk factor for developing Parkinson’s disease (PD). Activating glucosylceramidase...

  • Parkinson’s Disease Therapeutics Pipeline Program, 2024
    Targeting LRRK2 Dysfunction Using Aptamers in People with Parkinson’s Disease

    Study Rationale: Activating mutations in LRRK2 are a common cause of Parkinson’s disease (PD). We propose using aptamers to inhibit LRRK2. Aptamers are snippets of DNA or RNA that can fold into shape...

  • Parkinson’s Disease Therapeutics Pipeline Program, 2024
    IND-enabling Studies of a Molecule that Enhances Mitophagy as Disease-modifying Therapy for Parkinson's Disease

    Study Rationale: Studies show that Parkinson's disease (PD) is frequently associated with damage to mitochondria, structures that provide cells with the energy they need to function. In particular, a...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.